Maria Lopes-Virella to Autoantibodies
This is a "connection" page, showing publications Maria Lopes-Virella has written about Autoantibodies.
Connection Strength
3.599
-
Immune complexes containing malondialdehyde (MDA) LDL induce apoptosis in human macrophages. Clin Immunol. 2018 02; 187:1-9.
Score: 0.459
-
High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes. J Diabetes Complications. 2016 May-Jun; 30(4):693-9.
Score: 0.414
-
Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis. J Atheroscler Thromb. 2013; 20(10):743-54.
Score: 0.351
-
The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis. 2012 Oct; 224(2):526-31.
Score: 0.327
-
Clinical significance of the humoral immune response to modified LDL. Clin Immunol. 2010 Jan; 134(1):55-65.
Score: 0.261
-
Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clin Immunol. 2008 Jun; 127(3):394-400.
Score: 0.244
-
Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J Lipid Res. 2004 Oct; 45(10):1859-67.
Score: 0.187
-
Lipoprotein autoantibodies: measurement and significance. Clin Diagn Lab Immunol. 2003 Jul; 10(4):499-505.
Score: 0.174
-
The preparation of copper-oxidized LDL for the measurement of oxidized LDL antibodies by EIA. Atherosclerosis. 2000 Sep; 152(1):107-15.
Score: 0.143
-
Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. Diabetes. 2000 Jun; 49(6):1033-41.
Score: 0.140
-
Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol. 1999 Feb; 90(2):165-72.
Score: 0.128
-
Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls. Clin Immunol Immunopathol. 1997 Oct; 85(1):73-82.
Score: 0.117
-
F(ab')2 fragments of anti-oxidized LDL IgG attenuate vascular inflammation and atherogenesis in diabetic LDL receptor-deficient mice. Clin Immunol. 2016 Dec; 173:50-56.
Score: 0.107
-
Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler Thromb Vasc Biol. 1996 Feb; 16(2):222-9.
Score: 0.104
-
Comparing assays of antibodies to modified low-density lipoproteins. Clin Chem. 1995 Feb; 41(2):324-5.
Score: 0.097
-
Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res. 1993; 23(2):95-101.
Score: 0.084
-
Atherogenesis and the humoral immune response to modified lipoproteins. Atherosclerosis. 2008 Oct; 200(2):239-46.
Score: 0.061
-
The immunogenicity of modified lipoproteins. Ann N Y Acad Sci. 2005 Jun; 1043:367-78.
Score: 0.050
-
Autoimmune response to advanced glycosylation end-products of human LDL. J Lipid Res. 2003 Mar; 44(3):487-93.
Score: 0.042
-
Oxidized LDL-containing immune complexes induce Fc gamma receptor I-mediated mitogen-activated protein kinase activation in THP-1 macrophages. Arterioscler Thromb Vasc Biol. 1999 Jul; 19(7):1600-7.
Score: 0.033
-
Preparation of a human standard for determination of the levels of antibodies to oxidatively modified low-density lipoproteins. Clin Diagn Lab Immunol. 1998 Nov; 5(6):817-22.
Score: 0.031
-
Cytokines, modified lipoproteins, and arteriosclerosis in diabetes. Diabetes. 1996 Jul; 45 Suppl 3:S40-4.
Score: 0.027
-
Immune mechanisms in the pathogenesis of atherosclerosis. Adv Exp Med Biol. 1991; 285:383-92.
Score: 0.018